background: The aim of this study was to define determinants of fertility in patients treated conservatively for mucinous borderline ovarian tumours (MBOTs), and to compare outcomes after salpingo-oophorectomy or cystectomy.
Introduction
The most frequent histological subtypes of borderline ovarian tumours (BOTs) are serous and mucinous (MBOT) lesions. Conservative management in young patients is the gold standard for the surgical management of serous BOT. This treatment is safe in early-stage disease and also appears to be safe when proposed to patients with peritoneal implants (Fauvet et al., 2005; Morice, 2006; Tinelli et al., 2006; Swanton et al., 2007) . MBOTs are somewhat different. MBOTs are a complex group of tumours with several histological 'subtleties' or subtypes that could sometimes be morphologically considered as a real transition from benign mucinous tumours to invasive carcinoma (Ronnett et al., 2004; Hart, 2005) .
A recent paper seems to suggest that the prognosis of mucinous adenocarcinoma is worse than that of other histological subtypes (Alexandre et al., 2010; Hess et al., 2004) . Similar results have also been published concerning the case of mucinous borderline disease . Different papers also suggest the use of oophorectomy instead of cystectomy in MBOTs in order to reduce the risk of recurrence (particularly in the form of invasive carcinoma; Salomon et al., 2006; Uzan et al., 2010) . The aim of the current analysis is to investigate the impact of such a proposal on fertility results in patients with MBOTs. This paper is, to our knowledge, the first to be specifically dedicated to fertility results following conservative treatment of MBOTs.
Materials and Methods
Data concerning patients treated from June 1997 to April 2004 at/or referred to our institution and who had undergone surgery for an MBOT were reviewed. Patients were included in the current analysis if they exhibited the following three inclusion criteria already used in our previous report concerning oncological outcomes in MBOTs.
(1) The histological slides of the ovarian tumour were reviewed by the same reference pathologist (P.D.) with similar and homogeneous pathological criteria. (2) MBOTs associated with peritoneal pseudomyxoma were excluded. (3) Patient data included available information on patient characteristics, surgical management and a minimal follow-up of 1 year.
Patients who had undergone radical surgery (bilateral oophorectomy with or without hysterectomy) were excluded from the study and surgery consisted of conservative treatment (defined as conservation of the uterus and salvaging of at least a portion of one ovary). Patients were compared according to the kind of conservative treatment selected: group 1 (cystectomy) and group 2 [unilateral salpingo-oophorectomy (USO)]. If a restaging procedure had been performed and the cystectomy had been transformed into a USO, the patient was included in group 2. Surgical characteristics (route, staging classification, additional staging procedures and complete staging) were defined in a previous article concerning MBOTs (Koskas et al., 2010) .
To evaluate the probability of pregnancy after conservative surgery, we studied the subgroup of patients desiring pregnancy after surgery.
Two end-points were retained for the statistical analysis: the recurrence rate and the pregnancy rate. Recurrence-free survival and the pregnancy probability were determined using the Kaplan -Meier method. Recurrence-free survival and pregnancy rate were calculated in patients treated conservatively and desiring pregnancy. Pregnancy was defined as visualization of a gestational sac with demonstration of embryonic cardiac activity. To evaluate the impact of the kind of conservative treatment (cystectomy or USO) on recurrence and pregnancy rates, the log-rank test was used to compare the curves and to determine the P value. A P value of ,0.05 was considered significant.
Results
During the study period, 97 patients fulfilled the three inclusion criteria. We previously published a paper on the prognostic factors in this patient population (Koskas et al., 2010) . Among them, 69 were treated conservatively. During the initial procedure, 23 patients underwent a cystectomy and 3 of these underwent a USO during the restaging procedure. Among the 20 cystectomy cases and the 49 USO cases, 14 and 23 patients, respectively, desired pregnancy after surgery. Among these 37 patients, 31 had a minimum follow-up of 1 year and were finally included. The flow chart of patients included in the study is shown in Fig. 1 .
The mean age and BMI were, respectively, 26.8 (+ 5.8) years and 21.7 (+ 5.4) kg/m 2 . There were no significant differences between the two groups in terms of age, BMI, diagnostic circumstances, preoperative ultrasound examination, preoperative CA 125 and CA19 9 levels, histological characteristics and stage (Table I) . Only the use of frozen section analysis during surgery was significantly more frequent in the USO group (9/19 versus 1/12, P , 0.05). All patients were treated with surgery alone. No patient had bilateral MBOTs. Details concerning the surgical management during initial and restaging surgery (if performed) are given in Table II . Restaging surgery or complete staging never modified the initial stage of the disease (none of the patients had microscopic peritoneal spread without macroscopic suspicious lesions). One patient in the cystectomy group had pelvic peritoneal spread of the MBOT in the form of non-invasive implants. In that case, peritoneal disease was biopsied during surgery because it was macroscopically visible.
Recurrence analysis
Median follow-up was 59 months (range, 12-182) . Seven recurrences occurred in six patients.
In the cystectomy group, five patients developed a recurrence:
-Three cases were in the form of borderline disease after initial surgery (two lesions arose on the ipsilateral and one was on the contralateral ovary). One of the two patients who had initially relapsed on the ipsilateral ovary in the form of borderline disease developed a second recurrence in the form of an invasive tumour in the abdomen; the first relapse was at 18 months and the second was at 57 months after unilateral cystectomy. -Two cases were in the form of an invasive tumour in the abdomen (ovary, nodes, peritoneum or abdominal wall) after initial surgery, 27 and 36 months after a unilateral cystectomy.
In the USO group, one patient relapsed in the form of an invasive tumour in the abdomen (stage III ovarian cancer) 10 months after initial surgery. Among four patients who relapsed in the form of carcinoma, none were disease free at the time of the last contact.
Overall survival 5 years after the diagnosis was 91.3% (+ 5.9%). The 5-year recurrence-free survival rate after the diagnosis was 72.5% (+ 10.2%). The 5-year recurrence-free survival rate was higher in the oophorectomy group compared with the cystectomy group (94.7 versus 49.1%, P ¼ 0.041) (Fig. 2) .
Fertility analysis
In total, 16 pregnancies were achieved in 12 women. All pregnancies were spontaneous except one.
In the cystectomy group, five patients achieved seven pregnancies. They were all spontaneous except in the case of one patient who had undergone IVF because of severe partner dyspermia (10 × 106 sperm/ml). Five women gave birth to six babies. A twin pregnancy was achieved and a woman gave birth to two babies after surgery. One miscarriage occurred in one woman and one pregnancy was ongoing at the time of the last contact.
In the USO group, seven patients achieved nine pregnancies. They were all spontaneous. Seven women gave birth to eight babies. A twin pregnancy was achieved and one woman gave birth to two babies after surgery. One miscarriage occurred in one woman and one pregnancy was ongoing at the time of the last contact.
The 5-year pregnancy probability was 45.3% (+11.3%). The 5-year pregnancy probabilities were not statistically different between the cystectomy and oophorectomy groups (41.8 and 45.9%, respectively, P ¼ 0.66) (Fig. 3) . None of the other factors studied (age, gravidity, parity, CA125 level, surgical route, histological characteristics, size of the tumour and stage) were associated with fertility results (Table III) .
Discussion
This series raises several questions and comments. The key questions regarding the management of serous BOTs and MBOTs are different. Serous tumours arise bilaterally in 15-20% of cases and can be associated with peritoneal implants in 15 -40% of the cases (WHO Classification, 2003). The overall prognosis of serous tumours is excellent, even in the case of stage II or III disease, provided peritoneal implants are non-invasive . Thus, conservative management in young patients is considered the standard approach in early stage and stage II/III with non-invasive implants . The risk of recurrence on the spared ovary exists but does not compromise patient survival because most of these recurrences are 'borderline' tumours, have an excellent prognosis and are easily cured by a simple surgery. The risk of recurrence in the form of invasive carcinoma is very rare in this context (even in patients with stage II/III; Fauvet et al., 2005; Morice, 2006; Tinelli et al., 2006; Swanton et al., 2007) . As most recurrences occur on the spared ovary (in those studies), the most crucial issue in these serous tumours is to propose repeated conservative surgery (cystectomy) to patients with recurrent disease.
Mucinous borderline tumours are somewhat different. They are exceptionally bilateral and (if we exclude the particular case of peritoneal pseudomyxoma), most of these tumours are stage I lesions without peritoneal spread. Nevertheless, even if MBOTs are mostly limited to the ovary and unilateral, recent disturbing series suggest that such tumours can recur in the form of invasive carcinoma. In a recent analysis reported by our team, we observed a risk of recurrence in the form of invasive carcinoma in 13% of patients at 10 years (Koskas et al., 2010) . Other cases of progression into carcinoma have been reported in this context (Sumithran et al., 1988; Ji et al., 1996; Gotlieb et al., 1998; Zanetta et al., 2001; Suh-Burgmann, 2006; Yokoyama et al., 2006; Wong et al., 2007) . Nevertheless, apart from these 'isolated cases' (with some missing data concerning patient characteristics), other publications in the literature, which collectively report on up to 138 MBOTs (but without a pathological review), have not mentioned recurrences in the form of invasive carcinoma (Park et al., 2009 ).
If we consider that MBOTs can potentially evolve into invasive carcinoma, the clinical management of these tumours should aim to reduce this risk. In previous series, the only significant prognostic factor for the recurrence rate was the use of a cystectomy. This Figure 1 Flow chart of the patients included in the study. USO, unilateral salpingo-oophorectomy.
does not suggest that conservative surgery should be discontinued in young patients treated for (M)BOT because this is the standard management. Most of the few cases of recurrence in the form of invasive carcinoma after conservative management of stage I BOT reported in the literature were observed in mucinous tumours (whereas this situation is exceptional in serous BOT) and moreover, after a cystectomy (Salomon et al., 2006; Koskas et al., 2010) . The increased recurrence rate (compared with that following a salpingo-oophorectomy) is a well-known fact (mostly in the form of borderline disease), but we feel that such potential recurrences could compromise survival in the case of MBOTs. Such an increased rate of recurrences in the form of invasive disease can be explained in two ways. Firstly, mucinous tumours are a complex group of different diseases and the characterization of different histological entities in this subgroup is sometimes morphologically complex (Ronnett et al., 2004; Hart, 2005 Fertility and borderline ovarian mucinous tumours carcinoma. In such cases, conservative treatment using a salpingo-oophorectomy could be proposed, but a cystectomy is not safe in patients undergoing conservative management of epithelial ovarian cancer. Bilateral MBOTs are very rare, and bilateral surgery is exceptionally indicated in this context. With the exception of the particular case of patients with a previous history of salpingo-oophorectomy, oophorectomy should be preferred over cystectomy. Furthermore, in patients treated with a simple cystectomy for a unilateral MBOT (with a normal contralateral ovary), additional surgery including an adnexectomy should be discussed.
The other point requiring evaluation in this context is the impact on fertility of cystectomy versus oophorectomy results (particularly in MBOTs). Very few data on this point are available in the literature. In a series reported by Yinon et al. comparing the results of both procedures in borderline tumours (whatever the histological subtype), cystectomy and salpingo-oophorectomy seemed to be similar in terms of the recurrence rate, but the fertility rate was lower in patients treated using cystectomy (Yinon et al., 2007) . Nevertheless, the mean follow-up time was significantly different between the two groups (respectively 101 versus 65 months in patients who had undergone oophorectomy versus cystectomy). This is a substantial difference that could affect the results of the series by reducing the fertility rate as well as the recurrence rate in patients who had undergone a cystectomy (Yinon et al., 2007) .
Similarly, one randomized trial (this is the unique randomized trial concerning the treatment of BOT) compared salpingo-oophorectomy on the side of the biggest tumour and contralateral cystectomy or bilateral cystectomies in patients treated for bilateral tumours (Palomba et al., 2007) . After a follow-up period of 81 months, there was no difference between the two surgical procedures in terms of the cumulative rate of the first recurrence. Nevertheless, the cumulative pregnancy rate and the cumulative probability of the first pregnancy were higher in patients having undergone bilateral cystectomies compared with USO and contralateral cystectomy (Palomba et al., 2007) . Such results suggest that cystectomy should be preferred, if technically feasible (leaving in place a 'healthy part of both ovaries'), in order to improve the fertility rate. Nevertheless, this trial involved a limited number of patients (15 and 17, respectively, in the two arms) with (logically) a majority of serous tumours. In the multicentre study reported on by Fauvet et al. including all types of borderline tumours, the type of conservative treatment (cystectomy versus oophorectomy) had no impact on the fertility rate. The only prognostic factor that had an influence on the fertility results in that study was the patient's age (no pregnancy was observed in patients treated .40 years; Fauvet et al., 2005) . In the present series, involving 31 patients treated specifically for MBOTs and desiring pregnancy, there was no difference between cystectomy and salpingo-oophorectomy in terms of fertility results. Both groups were comparable, except concerning the rate of frozen section analyses that were more frequent in the group of patients having undergone an oophorectomy. This is logical because when tumours are diagnosed during the surgical procedure using frozen section analysis, a salpingo-oophorectomy is preferred over cystectomy in patients with a normal contralateral ovary. Nevertheless, the use of frozen section analysis had no influence on fertility results. Most of the pregnancies observed were spontaneous (15 out of 16) and the overall fertility rate was similar to that reported by other series and was not dependent on the type of conservative surgery used or on other patient characteristics (Fauvet et al., 2005; Morice, 2006; Tinelli et al., 2006; Swanton et al., 2007;  Table III ).
The present series suggests the choice of USO instead of a simple cystectomy in mucinous unilateral borderline ovarian tumours as it appears to be safer in terms of oncological results and has no impact on fertility results. 
